Aulos Bioscience

Aulos Bioscience is committed to revolutionizing cancer patient care with highly differentiated immuno-oncology treatments. Co-founded by ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company specializing in the bio-design of functional antibodies, Aulos initially developed a unique IL-2 targeted antibody, which it believes has the potential to become a first-class treatment for solid tumors.